FABP4 and colorectal carcinoma: Strengths of our investigation include the prospective study design, the ability to control for a variety of potential confounders in the biomarker analysis, and the use of MR enabling a further investigation of FABP-4 in relation to CRC risk circumventing certain types of bias common to studies of measured biomarkers.